‘Assault on common sense': Harvard, Penn professors criticize value-based compensation

Basing physician compensation on a pay-for-performance model “simply doesn’t work,” according to a Vox article written by Harvard Medical School population health professor Stephen Soumerai, ScD, and University of Pennsylvania health IT researcher Ross Koppel, PhD.

The professors classify such models as a “failure” and argue they may even lead to physicians avoiding treating sicker patients to ensure they receive bigger performance bonuses.

“They reward doctors for things they already do, like prescribing antihypertensive drugs. What’s more, the programs often use lousy, unreliable quality measures: For example, they might penalize doctors for not prescribing antibiotics to patients who are allergic to them. More troubling, there is evidence that such policies may even harm patients by encouraging unethical practice,” they wrote.

The solution, the pair argues, is more closely scrutinizing what they consider to be flawed research on these models’ effects on patient outcomes and focusing on identifying reasons for poor performance, not tying it to what a doctor makes.

For more on their harsh critique of these compensation models, including the broad changes made by the Medicare Access and CHIP Reauthorization Act (MACRA), click on the link below:  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.